Ann: Medical Cannabis Import & Export Licences Secured, page-172

The future revenue or the potential of MCL is not the issue but the current value of MCL and how that was calculated. The mere fact that that QBL can announce an expected 500 tonnes and only get 80, excuse it away as teething problems and not admit the gross miscalculation just adds weight to the argument that the price paid for MCL was equally overinflated and based on a market price alone without any substantial independent analysis of the actual business.
That same market has assessed the price paid for MCL and Medcan and judge it to be too high.

I repeat......
"Whilst I would like ,as a holder, nothing more than to see this share price climb, it cannot until the management realise that the price they negotiated for MCL which was based, according to one posters phone call with Sholom, solely on market price and not on any independent assessment/valuation, has been judged by that same market as too high a price.
The CR @ 0.08 is still in doubt
IMO No amount of ann's like the above between now and when QBL goes into suspension again will change that unless there is a radical re- evaluation of the deal/s that better reflects what the market actually thinks of their value."

I would applaud and retract my assessment of this current deal/s should any announcement be forthcoming that mention QBL or MCL or Medcan had a manufacture licence.
I will not retract if the missing manufacture piece of the business model involves AEB ( which I also hold) since I have already factored that into my current assessment of MCL and IMO so has the market.
I am disappointed, disillusioned and underwhelmed... and as ever clueless.. so all of the above could be a total misread